Logo Logo
Switch Language to German
Buske, C.; Hoster, Eva; Dreyling, Martin; Eimermacher, H.; Wandt, H.; Metzner, B.; Fuchs, R.; Bittenbring, J.; Wörmann, Bernhard; Hohloch, K.; Hess, G.; Ludwig, W. D.; Schimke, J.; Schmitz, S.; Kneba, M.; Reiser, M.; Graeven, U.; Klapper, Wolfram; Unterhalt, Michael; Hiddemann, Wolfgang (2009): The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). In: Leukemia, Vol. 23, No. 1: pp. 153-161
Full text not available from 'Open Access LMU'.